Discovery of ER α‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y 537 S Mutant Inhibition
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Dejun Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Engineering, Hoseo University, Asan, Republic of Korea. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Phytochemicals. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Breast cancer is known as a frequently diagnosed malignancy in women. Over 70% of cases express estrogen receptor α (ERα). The activation of ERα promotes tumor proliferation and progression. Furthermore, mutations in ERα lead to acquired resistance against standard endocrine therapies such as tamoxifen. The induced resistance posed a significant clinical challenge in metastatic breast cancer. In this study, research for identifying novel, naturally derived compounds to inhibit the Y537S‐mutated ERα was conducted using in silico methods supported by an in vitro cytotoxicity screen. Molecular docking and molecular dynamics simulations served as the primary in silico screening strategies. The top 2% of candidates were filtered from a docking screen of the IBS natural library composed of over 15,000 chemicals. From this group, 11 compounds were purchased and tested using a cell‐based cytotoxicity assay in MCF‐7 before advancing to detailed simulations. Five candidates were then advanced to 150 ns MD simulations. A post‐MD analysis followed, including MM‐PBSA binding free energy calculations and principal component analysis (PCA). The phytochemical ibs‐04156 was identified as the most promising overall candidate, predicted to maintain consistent stability across both the wild‐type and Y537S‐mutated ERα, while ibs‐18821 demonstrated potent mutant‐specific inhibition via an allosteric mechanism involving spatial deviations in distal helices H3 and H11. This result shows that mutated ERα can be potentially targeted by bioactive phytochemical scaffolds found through molecular modeling, presenting a potential therapeutic strategy for metastatic breast cancer resistant to therapies such as tamoxifen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Environmental Engineering, Hoseo University, Asan, Republic of Korea.
- Pet-Loss Center, Hoseo University, Asan, Republic of Korea.
- Department of Food Science & Technology, Hoseo University, Asan, Republic of Korea.
- Department of Bio-Applied Toxicology, Hoseo University, Asan, Republic of Korea.
ORCID-Profile: Dejun Jiang, Youngjin Choi
Förderung
- National Research Foundation of Korea
Zitieren
APA
Jiang, D., Kwon, O. W., Joe, H., Shin, E., Cho, S., Kwon, H. K., & Choi, Y. (2026). Discovery of ER α‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y 537 S Mutant Inhibition. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70393
Vancouver
Jiang D, Kwon OW, Joe H, Shin E, Cho S, Kwon HK, et al. Discovery of ER α‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y 537 S Mutant Inhibition. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70393
BibTeX
@article{Jiang2026,
author = {Jiang, Dejun and Kwon, Oh Wook and Joe, Hanbin and Shin, Euijeong and Cho, Sungjoon and Kwon, Hyuk-Ku and Choi, Youngjin},
title = {Discovery of ER α‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y 537 S Mutant Inhibition},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70393}
}
EUVIMED